Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Lanson-Bcc

Start price
Target price
Perf. (%)
€26.80
13.09.21
€29.00
13.09.22
20.15%
14.09.22

Could be worthwhile Investment >10% per year
Frosta AG

Start price
Target price
Perf. (%)
€92.60
08.09.21
-
08.09.22
-36.93%
09.09.22

buy
Agrana Beteiligungs AG

Start price
Target price
Perf. (%)
€18.30
09.08.21
-
09.08.24
-27.32%
11.03.24

Could be worthwhile Investment >10% per year
Aurora Cannabis Inc.

Start price
Target price
Perf. (%)
€6.18
08.08.21
-
08.08.22
-3.23%
18.10.21

positive Cash Flow expected
Good rating
Normal challenges to pay loans and raise capital
ROE lower than 10% per year
buy
Perdoceo Education Corp.

Start price
Target price
Perf. (%)
€10.30
12.07.21
-
12.07.22
-5.83%
13.03.22

buy
Sunopta Inc.

Start price
Target price
Perf. (%)
€9.85
08.07.21
-
08.07.22
-11.17%
08.07.22

buy
Vuzix Corp.

Start price
Target price
Perf. (%)
€14.31
08.07.21
-
08.07.22
-49.81%
08.07.22

buy
Apollo Medical Holdings, Inc.

Start price
Target price
Perf. (%)
€67.50
08.07.21
-
08.07.22
-38.67%
02.03.22

buy
Bonduelle S.A.

Start price
Target price
Perf. (%)
€21.05
08.07.21
€25.00
08.07.22
-29.69%
08.07.22

Laurent-Perrier S.A.

Start price
Target price
Perf. (%)
€91.80
19.06.21
€88.00
19.06.22
6.97%
20.06.22

Could be worthwhile Investment >10% per year
buy
Hawesko Holding AG

Start price
Target price
Perf. (%)
€56.60
15.06.21
€66.00
15.06.22
-16.61%
16.06.22

Future proof or reliable business model
Top 10 in its market
Standard Investments for future growth
Good rating
buy
KWS Saat SE & Co. KGaA

Start price
Target price
Perf. (%)
€76.60
01.06.21
-
01.06.22
-18.80%
02.06.22

buy
Aurora Cannabis Inc.

Start price
Target price
Perf. (%)
€7.45
28.05.21
€6.90
28.05.22
-29.94%
05.12.21

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
Ingles Markets Inc

Start price
Target price
Perf. (%)
€50.00
23.05.21
€60.00
23.05.22
61.00%
24.05.22

Could be worthwhile Investment >10% per year
buy
Bonduelle S.A.

Start price
Target price
Perf. (%)
€24.00
11.05.21
€25.00
11.05.22
-5.42%
08.11.21

Could be worthwhile Investment >10% per year
buy
Bongrain S.A. Inh.

Start price
Target price
Perf. (%)
€73.20
03.05.21
€78.00
03.05.22
-13.39%
04.05.22

Could be worthwhile Investment >10% per year
Aurora Cannabis Inc.

Start price
Target price
Perf. (%)
€6.67
19.04.21
€5.90
19.04.22
11.61%
28.05.21

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
StoneMor Inc.

Start price
Target price
Perf. (%)
€1.87
17.04.21
-
17.04.22
24.06%
18.04.22

Could be very worthwhile Investment >20% year
buy
Sektkellerei Schloss Wachenheim AG

Start price
Target price
Perf. (%)
€15.90
28.03.21
€18.00
28.03.23
13.21%
30.05.21

Known brand
Fair valuation
Aurora Cannabis Inc.

Start price
Target price
Perf. (%)
€8.60
20.03.21
€5.00
04.11.21
-31.08%
05.11.21

Risky Investment
Revenue decline > 20% expected
EBIT decline/stagnation expected
buy
Aurora Cannabis Inc.

Start price
Target price
Perf. (%)
€8.12
08.03.21
€9.00
3.39%
10.03.21

Could be very worthwhile Investment >20% year
Top 10 in its market
High valuation
Risky balance sheet
buy
Aurora Cannabis Inc.

Start price
Target price
Perf. (%)
€8.12
08.03.21
-
08.03.22
-1.79%
24.03.21

positive Cash Flow expected
Good rating
Normal challenges to pay loans and raise capital
ROE lower than 10% per year
buy
Aurora Cannabis Inc.

Start price
Target price
Perf. (%)
€8.12
08.03.21
-
5.98%
21.03.21

Risky Investment
Veru Inc

Start price
Target price
Perf. (%)
€15.90
16.02.21
€9.00
16.02.22
-20.13%
18.02.21

Growths faster than the competition
Higher risks for its business
overvalued
Risky balance sheet
Veru Inc

Start price
Target price
Perf. (%)
€18.30
10.02.21
-
10.02.22
-70.74%
11.02.22

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Probably not worthwhile Investment
Lower EBIT Margin than peer group